Categories: News

NYSE Content Update: Global Medical Response to Go Public After $479 Million IPO

NYSE issues a pre-market daily advisory direct from the trading floor.

- Advertisement -

NEW YORK, May 13, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Ashley Mastronardi delivers the pre-market update on May 13th

- Advertisement -
  • Equities are higher Wednesday morning after the Bureau of Labor Statistics released the April PPI report earlier today.
  • Shares of NYSX component Sea Limited (NYSE: SE) rose more than 13% Tuesday after the company reported 38% year-over-year revenue growth.
  • Global Medical Response (NYSE: GMRS) CEO Nick Loporcaro will join NYSE Live to reveal what’s next as his company makes its trading debut.
  • Rollins (NYSE: ROL) CFO Kenneth Krause will join Taking Stock to preview the company’s 2026 Investor and Analyst Conference later this week.

Opening Bell
Global Medical Response (NYSE: GMRS) celebrates its IPO

- Advertisement -

Closing Bell
Rollins (NYSE: ROL) continues its journey to modernize through growth and innovation

- Advertisement -

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App: TV.NYSE.com

- Advertisement -

 

- Advertisement -

Video – https://mma.prnewswire.com/media/2979221/NYSE_May_13_Market_Update.mp4 
Photo – https://mma.prnewswire.com/media/2979220/NYSE_Disney.jpg 
Logo – https://mma.prnewswire.com/media/2581322/5968548/New_York_Stock_Exchange_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-update-global-medical-response-to-go-public-after-479-million-ipo-302770943.html

- Advertisement -

Recent Posts

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogrens Disease at EULAR 2026

ALKIVIA+ data in myositis indicate efgartigimod provides sustained, clinically meaningful improvements and consistent safety RHO+…

49 minutes ago

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed…

49 minutes ago

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus…

49 minutes ago

GIGABYTE Unveils Next-Generation Gaming Peripherals with AORUS K10 INFINITY Keyboard and M10 INFINITY Mouse at COMPUTEX 2026

TAIPEI, June 3, 2026 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, unveiled its next-generation…

50 minutes ago

Nationwide Celebrations mark Ruskin Bond’s 92nd Birthday

GURUGRAM, India, June 2, 2026 /PRNewswire/ -- On May 19, 2026, 92 bookstores across India…

7 hours ago

Canovation and CANPACK Formalize Collaboration to Accelerate CanReseal Toward Commercial Launch

The companies will align Canovation's resealable aluminum can-end technology with CANPACK's global manufacturing expertise to…

7 hours ago